Cytokines in bipolar disorder vs. healthy control subjects: A systematic review and meta-analysis

Journal of Psychiatric Research

Volumn 47, Issue 9, 2013, Pages 1119-1133

  Munkholm, Klaus ^a   Braüner, Julie Vestergaard ^a   Kessing, Lars Vedel ^a   Vinberg, Maj ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Biomarker; Bipolar disorder; Cytokines; Inflammation; Meta analysis; Review

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1;

BIPOLAR DISORDER; DATA EXTRACTION; EMBASE; HUMAN; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; PSYCINFO; REVIEW; SYSTEMATIC REVIEW;

EID: 84880133128     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2013.05.018     Document Type: Review

References (155)

1. Altamura A.C., Serati M., Albano A., Paoli R.A., Glick I.D., Dell'Osso B. An epidemiologic and clinical overview of medical and psychopathological comorbidities in major psychoses. European Archives of Psychiatry and Clinical Neuroscience 2011, 261:489-508.
2. Angst F., Stassen H.H., Clayton P.J., Angst J. Mortality of patients with mood disorders: follow-up over 34-38 years. Journal of Affective Disorders 2002, 68:167-181.
3. Banks W.A., Kastin A.J., Broadwell R.D. Passage of cytokines across the blood-brain barrier. Neuroimmunomodulation 1995, 2:241-248.
4. Barbosa I.G., Huguet R.B., Mendonca V.A., Sousa L.P., Neves F.S., Bauer M.E., et al. Increased plasma levels of soluble TNF receptor I in patients with bipolar disorder. European Archives of Psychiatry and Clinical Neuroscience 2011, 261:139-143.
5. Barbosa I.G., Rocha N.P., de Miranda A.S., Magalhaes P.V., Huguet R.B., de Souza L.P., et al. Increased levels of adipokines in bipolar disorder. Journal of Psychiatric Research 2012, 46:389-393.
6. Barbosa I.G., Rocha N.P., Huguet R.B., Ferreira R.A., Salgado J.V., Carvalho L.A., et al. Executive dysfunction in euthymic bipolar disorder patients and its association with plasma biomarkers. Journal of Affective Disorders 2012, 137:151-155.
7. Behrens M.M., Ali S.S., Dugan L.L. Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia. Journal of Neuroscience 2008, 28:13957-13966.
8. Bellani M., Bergami A., Tomelleri L., Perlini C., Cerruti S., Ferro A., et al. Altered mRNA levels of chemokines and cytokines in schizophrenia and bipolar disorder. Schizophrenia Research 2010, 117(2--3):251-252.
9. Berk M. Neuroprogression: pathways to progressive brain changes in bipolar disorder. International Journal of Neuropsychopharmacology 2009, 12:441-445.
10. Berk M., Kapczinski F., Andreazza A.C., Dean O.M., Giorlando F., Maes M., et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neuroscience and Biobehavioral Reviews 2011, 35:804-817.
11. Beumer W., Gibney S.M., Drexhage R.C., Pont-Lezica L., Doorduin J., Klein H.C., et al. The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes. Journal of Leukocyte Biology 2012, 92:959-975.
12. Boufidou F., Nikolaou C., Alevizos B., Liappas I.A., Christodoulou G.N. Cytokine production in bipolar affective disorder patients under lithium treatment. Journal of Affective Disorders 2004, 82:309-313.
13. Breunis M.N., Kupka R.W., Nolen W.A., Suppes T., Denicoff K.D., Leverich G.S., et al. High numbers of circulating activated T cells and raised levels of serum IL-2 receptor in bipolar disorder. Biological Psychiatry 2003, 53:157-165.
14. Brietzke E., Kauer-Sant'Anna M., Teixeira A.L., Kapczinski F. Abnormalities in serum chemokine levels in euthymic patients with bipolar disorder. Brain, Behavior, and Immunity 2009, 23:1079-1082.
15. Brietzke E., Stabellini R., Grassis-Oliveira R., Lafer B. Cytokines in bipolar disorder: recent findings, deleterious effects but promise for future therapeutics. CNS Spectrums 2011, 16.
16. Brietzke E., Stertz L., Fernandes B.S., Kauer-Sant'anna M., Mascarenhas M., Escosteguy Vargas A., et al. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. Journal of Affective Disorders 2009, 116:214-217.
17. Brietzke E., Teixeira A.L. Similar immune profile in bipolar disorder and schizophrenia: selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor. Bipolar Disorders 2010, 12:453-454.
18. Cetin T., Guloksuz S., Cetin E.A., Gazioglu S.B., Deniz G., Oral E.T., et al. Plasma concentrations of soluble cytokine receptors in euthymic bipolar patients with and without subsyndromal symptoms. BMC Psychiatry 2012, 12:158.
19. Chae C.U., Lee R.T., Rifai N., Ridker P.M. Blood pressure and inflammation in apparently healthy men. Hypertension 2001, 38:399-403.
20. Chen G., Goeddel D.V. TNF-R1 signaling: a beautiful pathway. Science 2002, 296:1634-1635.
21. Couzin-Frankel J. Inflammation bares a dark side. Science 2010, 330:1621.
22. Cunha A.B., Andreazza A.C., Gomes F.A., Frey B.N., da Silveira L.E., Goncalves C.A., et al. Investigation of serum high-sensitive C-reactive protein levels across all mood states in bipolar disorder. European Archives of Psychiatry and Clinical Neuroscience 2008, 258:300-304.
23. Dahlman I., Kaaman M., Olsson T., Tan G.D., Bickerton A.S., Wahlen K., et al. Aunique role of monocyte chemoattractant protein 1 among chemokines in adipose tissue of obese subjects. Journal of Clinical Endocrinology and Metabolism 2005, 90:5834-5840.
24. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nature Reviews Neuroscience 2008, 9:46-56.
25. De Berardis D., Conti C.M., Campanella D., Carano A., Scali M., Valchera A., et al. Evaluation of C-reactive protein and total serum cholesterol in adult patients with bipolar disorder. International Journal of Immunopathology and Pharmacology 2008, 21:319-324.
26. DerSimonian R., Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986, 7:177-188.
27. Dickerson F. Immunologic abnormalities associated with mania. Brain, Behavior, and Immunity 2010, 24:S54.
28. Dickerson F., Copp C., Stallings C., Origoni A., Khushalani S., Yolken R. C-Reactive protein in acute mania: a longitudinal study. Bipolar Disorders 2009, 11(S1):34.
29. Dickerson F., Stallings C., Origoni A., Boronow J., Yolken R. Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2007, 31:952-955.
30. do Prado C.H., Rizzo L.B., Wieck A., Lopes R.P., Teixeira A.L., Grassi-Oliveira R., et al. Reduced regulatory T cells are associated with higher levels of Th1/TH17 cytokines and activated MAPK in type 1 bipolar disorder. Psychoneuroendocrinology 2012.
31. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., et al. Ameta-analysis of cytokines in major depression. Biological Psychiatry 2010, 67:446-457.
32. Drexhage H.A., Drexhage R.C., Mesman E., Van Beveren N., Hillegers M., Nolen W.A. Immune activation in psychiatric and pre-psychiatric disease. European Psychiatry 2011, 26.
33. Drexhage R.C., Hoogenboezem T.H., Versnel M.A., Berghout A., Nolen W.A., Drexhage H.A. The activation of monocyte and T cell networks in patients with bipolar disorder. Brain, Behavior, and Immunity 2011, 25:1206-1213.
34. Drexhage R.C., Knijff E.M., Padmos R.C., Heul-Nieuwenhuijzen L., Beumer W., Versnel M.A., et al. The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert Review of Neurotherapeutics 2010, 10:59-76.
35. Drexhage R.C., van der Heul-Nieuwenhuijsen L., Padmos R.C., van Beveren N., Cohen D., Versnel M.A., et al. Inflammatory gene expression in monocytes of patients with schizophrenia: overlap and difference with bipolar disorder. A study in naturalistically treated patients. International Journal of Neuropsychopharmacology 2010, 13:1369-1381.
36. Duman R.S. Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromolecular Medicine 2004, 5:11-25.
37. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
38. Egger M., Schneider M., Davey Smith G. Spurious precision? Meta-analysis of observational studies. BMJ 1998, 316:140-144.
39. Egger M., Smith G.D. Meta-analysis. Potentials and promise. BMJ 1997, 315:1371-1374.
40. Egger M., Smith G.D., Phillips A.N. Meta-analysis: principles and procedures. BMJ 1997, 315:1533-1537.
41. Ekdahl C.T., Claasen J.H., Bonde S., Kokaia Z., Lindvall O. Inflammation is detrimental for neurogenesis in adult brain. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:13632-13637.
42. Esposito K., Pontillo A., Di Palo C., Giugliano G., Masella M., Marfella R., et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003, 289:1799-1804.
43. Fernandes B.S., Gama C.S., Cereser K.M., Yatham L.N., Fries G.R., Colpo G., et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. Journal of Psychiatric Research 2011, 45:995-1004.
44. Fontenot J.D., Rasmussen J.P., Gavin M.A., Rudensky A.Y. Afunction for interleukin 2 in Foxp3-expressing regulatory T cells. Nature Immunology 2005, 6:1142-1151.
45. Gardner A., Boles R.G. Beyond the serotonin hypothesis: mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2011, 35:730-743.
46. Gildengers A., Tatsuoka C., Bialko C., Cassidy K.A., Al Jurdi R.K., Gyulai L., et al. Correlates of treatment response in depressed older adults with bipolar disorder. Journal of Geriatric Psychiatry and Neurology 2012, 25:37-42.
47. Goldstein B.I., Kemp D.E., Soczynska J.K., McIntyre R.S. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. Journal of Clinical Psychiatry 2009, 70:1078-1090.
48. Grande I., Magalhaes P.V., Kunz M., Vieta E., Kapczinski F. Mediators of allostasis and systemic toxicity in bipolar disorder. Physiology and Behavior 2012, 106:46-50.
49. Guloksuz S., Altinbas K., Aktas Cetin E., Kenis G., Bilgic Gazioglu S., Deniz G., et al. Evidence for an association between tumor necrosis factor-alpha levels and lithium response. Journal of Affective Disorders 2012, 143:148-152.
50. Guloksuz S., Cetin E.A., Cetin T., Deniz G., Oral E.T., Nutt D.J. Cytokine levels in euthymic bipolar patients. Journal of Affective Disorders 2010, 126:458-462.
51. Haddad J.J., Saade N.E., Safieh-Garabedian B. Cytokines and neuro-immune-endocrine interactions: a role for the hypothalamic-pituitary-adrenal revolving axis. Journal of Neuroimmunology 2002, 133:1-19.
52. Higgins J., Thompson S., Deeks J., Altman D. Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice. Journal of Health Services Research and Policy 2002, 7:51-61.
53. Himmerich H., Koethe D., Schuld A., Yassouridis A., Pollmacher T. Plasma levels of leptin and endogenous immune modulators during treatment with carbamazepine or lithium. Psychopharmacology 2005, 179:447-451.
54. Hope S., Dieset I., Agartz I., Steen N.E., Ueland T., Melle I., et al. Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia. Journal of Psychiatric Research 2011, 45:1608-1616.
55. Hope S., Melle I., Aukrust P., Steen N.E., Birkenaes A.B., Lorentzen S., et al. Similar immune profile in bipolar disorder and schizophrenia: selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor. Bipolar Disorders 2009, 11:726-734.
56. Hope S., Melle I., Ueland T., Lorentzen S., Steen N.E., Berg A.O., et al. Interleukin 1 receptor antagonist and tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder. Schizophrenia Bulletin 2011, 37:115-116.
57. Hornig M., Goodman D.B., Kamoun M., Amsterdam J.D. Positive and negative acute phase proteins in affective subtypes. Journal of Affective Disorders 1998, 49:9-18.
58. Hsiao Y.L., Wu Y.S., Wu J.Y., Hsu M.H., Chen H.C., Lee S.Y., et al. Neuropsychological functions in patients with bipolar I and bipolar II disorder. Bipolar Disorders 2009, 11:547-554.
59. Huang T.L., Lin F.C. High-sensitivity C-reactive protein levels in patients with major depressive disorder and bipolar mania. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2007, 31:370-372.
60. Haack M., Hinze-Selch D., Fenzel T., Kraus T., Kuhn M., Schuld A., et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. Journal of Psychiatric Research 1999, 33:407-418.
61. Imhof A., Froehlich M., Brenner H., Boeing H., Pepys M.B., Koenig W. Effect of alcohol consumption on systemic markers of inflammation. Lancet 2001, 357:763-767.
62. Imura H. Endocrine and metabolic manifestations associated with infectious and inflammatory diseases. FEMS Immunology and Medical Microbiology 1997, 18:221-226.
63. Jamrozinski K., Gruber O., Kemmer C., Falkai P., Scherk H. Neurocognitive functions in euthymic bipolar patients. Acta Psychiatrica Scandinavica 2009, 119:365-374.
64. Jones S.A., Horiuchi S., Topley N., Yamamoto N., Fuller G.M. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB Journal 2001, 15:43-58.
65. Jones S.A., Rose-John S. The role of soluble receptors in cytokine biology: the agonistic properties of the sIL-6R/IL-6 complex. Biochimica et Biophysica Acta 2002, 1592:251-263.
66. Kang K., Kim Y.J., Kim Y.H., Roh J.N., Nam J.M., Kim P.Y., et al. Lithium pretreatment reduces brain injury after intracerebral hemorrhage in rats. Neurological Research 2012, 34:447-454.
67. Kapczinski F., Dal-Pizzol F., Teixeira A.L., Magalhaes P.V., Kauer-Sant'Anna M., Klamt F., et al. Peripheral biomarkers and illness activity in bipolar disorder. Journal of Psychiatric Research 2011, 45:156-161.
68. Kapczinski F., Dal-Pizzol F., Teixeira A.L., Magalhaes P.V., Kauer-Sant'Anna M., Klamt F., et al. Asystemic toxicity index developed to assess peripheral changes in mood episodes. Molecular Psychiatry 2010, 15:784-786.
69. Kapczinski F., Dias V.V., Kauer-Sant'Anna M., Brietzke E., Vazquez G.H., Vieta E., et al. The potential use of biomarkers as an adjunctive tool for staging bipolar disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2009, 33:1366-1371.
70. Kapczinski F., Vieta E., Andreazza A.C., Frey B.N., Gomes F.A., Tramontina J., et al. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neuroscience and Biobehavioral Reviews 2008, 32:675-692.
71. Kauer-Sant'Anna M. Brain-derived neurotrophic factor and inflammatory markers in patients with early-vs. late-state bipolar disorder. Biological Psychiatry 2011, 1:123S.
72. Kauer-Sant'Anna M., Kapczinski F., Andreazza A.C., Bond D.J., Lam R.W., Young L.T., et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. International Journal of Neuropsychopharmacology 2009, 12:447-458.
73. Kemp D.E., Gao K., Chan P.K., Ganocy S.J., Findling R.L., Calabrese J.R. Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine/metabolic system and treatment outcome. Bipolar Disorders 2010, 12:404-413.
74. Kim Y.K., Jung H.G., Myint A.M., Kim H., Park S.H. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. Journal of Affective Disorders 2007, 104:91-95.
75. Kim Y.K., Myint A.M., Lee B.H., Han C.S., Lee S.W., Leonard B.E., et al. T-helper types 1, 2, and 3 cytokine interactions in symptomatic manic patients. Psychiatry Research 2004, 129:267-272.
76. Kim Y.K., Suh I.B., Kim H., Han C.S., Lim C.S., Choi S.H., et al. The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs. Molecular Psychiatry 2002, 7:1107-1114.
77. Knijff E.M., Breunis M.N., Kupka R.W., de Wit H.J., Ruwhof C., Akkerhuis G.W., et al. An imbalance in the production of IL-1beta and IL-6 by monocytes of bipolar patients: restoration by lithium treatment. Bipolar Disorders 2007, 9:743-753.
78. Knijff E.M., Breunis M.N., van Geest M.C., Kupka R.W., Ruwhof C., de Wit H.J., et al. Arelative resistance of T cells to dexamethasone in bipolar disorder. Bipolar Disorders 2006, 8:740-750.
79. Kunz M., Cereser K.M., Goi P.D., Fries G.R., Teixeira A.L., Fernandes B.S., et al. Serum levels of IL-6, IL-10 and TNF-alpha in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance. Revista Brasileira de Psiquiatria 2011, 33:268-274.
80. Kunz M., Cereser K.M.M., Fries G.R., Teixeira A., Fernandes B.S., Kauer-Sant'Anna M., et al. Serum levels of Il6, Il10 and TNF-alpha in patients with bipolar disorder in euthymia and with schizophrenia: differences in pro and anti-inflammatory balance. Biological Psychiatry 2010, 1:132S.
81. Kupfer D.J. The increasing medical burden in bipolar disorder. JAMA 2005, 293:2528-2530.
82. Leboyer M., Soreca I., Scott J., Frye M., Henry C., Tamouza R., et al. Can bipolar disorder be viewed as a multi-system inflammatory disease?. Journal of Affective Disorders 2012, 141:1-10.
83. Legros S., Mendlewicz J., Wybran J. Immunoglobulins, autoantibodies and other serum protein fractions in psychiatric disorders. European Archives of Psychiatry and Neurological Sciences 1985, 235:9-11.
84. Leonard B.E. The immune system, depression and the action of antidepressants. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2001, 25:767-780.
85. Lindqvist D., Janelidze S., Hagell P., Erhardt S., Samuelsson M., Minthon L., et al. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biological Psychiatry 2009, 66:287-292.
86. Liu H.C., Yang Y.Y., Chou Y.M., Chen K.P., Shen W.W., Leu S.J. Immunologic variables in acute mania of bipolar disorder. Journal of Neuroimmunology 2004, 150:116-122.
87. Maes M., Bosmans E., Calabrese J., Smith R., Meltzer H.Y. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. Journal of Psychiatric Research 1995, 29:141-152.
88. Maes M., Delange J., Ranjan R., Meltzer H.Y., Desnyder R., Cooremans W., et al. Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Research 1997, 66:1-11.
89. Maier B., Laurer H.L., Rose S., Buurman W.A., Marzi I. Physiological levels of pro- and anti-inflammatory mediators in cerebrospinal fluid and plasma: a normative study. Journal of Neurotrauma 2005, 22:822-835.
90. Manji H.K., Moore G.J., Rajkowska G., Chen G. Neuroplasticity and cellular resilience in mood disorders. Molecular Psychiatry 2000, 5:578-593.
91. Manning P.J., Sutherland W.H., McGrath M.M., de Jong S.A., Walker R.J., Williams M.J. Postprandial cytokine concentrations and meal composition in obese and lean women. Obesity (Silver Spring) 2008, 16:2046-2052.
92. Marie C., Pitton C., Fitting C., Cavaillon J.M. Regulation by anti-inflammatory cytokines (IL-4, IL-10, IL-13, TGFbeta)of interleukin-8 production by LPS- and/or TNFalpha-activated human polymorphonuclear cells. Mediators of Inflammation 1996, 5:334-340.
93. Marz P., Heese K., Dimitriades-Schmutz B., Rose-John S., Otten U. Role of interleukin-6 and soluble IL-6 receptor in region-specific induction of astrocytic differentiation and neurotrophin expression. Glia 1999, 26:191-200.
94. Marz P., Herget T., Lang E., Otten U., Rose-John S. Activation of gp130 by IL-6/soluble IL-6 receptor induces neuronal differentiation. European Journal of Neuroscience 1997, 9:2765-2773.
95. McIntyre R.S., Rasgon N.L., Kemp D.E., Nguyen H.T., Law C.W., Taylor V.H., et al. Metabolic syndrome and major depressive disorder: co-occurrence and pathophysiologic overlap. Current Diabetes Reports 2009, 9:51-59.
96. Middle F., Jones I., Robertson E., Lendon C., Craddock N. Tumour necrosis factor alpha and bipolar affective puerperal psychosis. Psychiatric Genetics 2000, 10:195-198.
97. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biological Psychiatry 2009, 65:732-741.
98. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biological Psychiatry 2011, 70:663-671.
99. Modabbernia A., Taslimi S., Brietzke E., Ashrafi M. Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biological Psychiatry 2013.
100. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009, 339:b2535.
101. Monje M.L., Toda H., Palmer T.D. Inflammatory blockade restores adult hippocampal neurogenesis. Science 2003, 302:1760-1765.
102. Munkholm K., Vinberg M., Berk M., Kessing L.V. State-related alterations of gene expression in bipolar disorder: a systematic review. Bipolar Disorders 2012, 14:684-696.
103. Munkholm K., Vinberg M., Vedel Kessing L. Cytokines in bipolar disorder: a systematic review and meta-analysis. Journal of Affective Disorders 2013, 144:16-27.
104. Nahman S., Belmaker R.H., Azab A.N. Effects of lithium on lipopolysaccharide-induced inflammation in rat primary glia cells. Innate Immunity 2012, 18:447-458.
105. Naik E., Dixit V.M. Mitochondrial reactive oxygen species drive proinflammatory cytokine production. Journal of Experimental Medicine 2011, 208:417-420.
106. Nery F.G., Monkul E.S., Hatch J.P., Fonseca M., Zunta-Soares G.B., Frey B.N., et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Human Psychopharmacology 2008, 23:87-94.
107. Ng F., Berk M., Dean O., Bush A.I. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. International Journal of Neuropsychopharmacology 2008, 11:851-876.
108. O'Brien S.M., Scully P., Scott L.V., Dinan T.G. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. Journal of Affective Disorders 2006, 90:263-267.
109. O'Connor M.F., Bower J.E., Cho H.J., Creswell J.D., Dimitrov S., Hamby M.E., et al. To assess, to control, to exclude: effects of biobehavioral factors on circulating inflammatory markers. Brain, Behavior, and Immunity 2009, 23:887-897.
110. Ortiz-Dominguez A., Hernandez M.E., Berlanga C., Gutierrez-Mora D., Moreno J., Heinze G., et al. Immune variations in bipolar disorder: phasic differences. Bipolar Disorders 2007, 9:596-602.
111. Padmos R.C., Hillegers M.H., Knijff E.M., Vonk R., Bouvy A., Staal F.J., et al. Adiscriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Archives of General Psychiatry 2008, 65:395-407.
112. Pandey G.N. Proinflammatory cytokines and brain-derived neurotrophic factor in patients with pediatric bipolar disorders. Biological Psychiatry 2011, 1:123S.
113. Papanicolaou D.A., Vgontzas A.N. Interleukin-6: the endocrine cytokine. Journal of Clinical Endocrinology and Metabolism 2000, 85:1331-1333.
114. Park K.M., Bowers W.J. Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction. Cellular Signalling 2010, 22:977-983.
115. Peters J.L., Mengersen K.L. Meta-analysis of repeated measures study designs. Journal of Evaluation in Clinical Practice 2008, 14:941-950.
116. Pischon T., Hankinson S.E., Hotamisligil G.S., Rifai N., Rimm E.B. Leisure-time physical activity and reduced plasma levels of obesity-related inflammatory markers. Obesity Research 2003, 11:1055-1064.
117. Pollmacher T., Haack M., Schuld A., Kraus T., Hinze-Selch D. Effects of antipsychotic drugs on cytokine networks. Journal of Psychiatric Research 2000, 34:369-382.
118. Poppitt S.D., Keogh G.F., Lithander F.E., Wang Y., Mulvey T.B., Chan Y.K., et al. Postprandial response of adiponectin, interleukin-6, tumor necrosis factor-alpha, and C-reactive protein to a high-fat dietary load. Nutrition 2008, 24:322-329.
119. Powrie F., Menon S., Coffman R.L. Interleukin-4 and interleukin-10 synergize to inhibit cell-mediated immunity invivo. European Journal of Immunology 1993, 23:3043-3049.
120. Prossin A., McInnis M., Zalcman S., Ellingrod V. IL-6 is associated with metabolic syndrome in bipolar disorder. Brain, Behavior, and Immunity 2010, 24:S47.
121. Quan N., Banks W.A. Brain-immune communication pathways. Brain, Behavior, and Immunity 2007, 21:727-735.
122. Rajkowska G. Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biological Psychiatry 2000, 48:766-777.
123. Rao J.S., Harry G.J., Rapoport S.I., Kim H.W. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Molecular Psychiatry 2010, 15:384-392.
124. Rapaport M.H. Immune parameters in euthymic bipolar patients and normal volunteers. Journal of Affective Disorders 1994, 32:149-156.
125. Rapaport M.H., Guylai L., Whybrow P. Immune parameters in rapid cycling bipolar patients before and after lithium treatment. Journal of Psychiatric Research 1999, 33:335-340.
126. Remlinger-Molenda A., Wojciak P., Kostrzewa A., Karczewski J., Wiktorowicz K., Rybakowski J.K. Cytokine profiles in bipolar affective disorder during acute episodes and in remission. European Neuropsychopharmacology 2010, 20:S415-S416.
127. Remlinger-Molenda A., Wojciak P., Michalak M., Karczewski J., Rybakowski J.K. Selected cytokine profiles during remission in bipolar patients. Neuropsychobiology 2012, 66:193-198.
128. Remlinger A., Wojciak P., Karczewski J., Kostrzewa A., Wiktorowicz K., Rybakowski J.K. The effect of mania on cytokine status in bipolar illness. Journal of Cancer Education 2009, 24:S462.
129. Rybakowski J.K. Antiviral and immunomodulatory effect of lithium. Pharmacopsychiatry 2000, 33:159-164.
130. Schneider-Brachert W., Tchikov V., Neumeyer J., Jakob M., Winoto-Morbach S., Held-Feindt J., et al. Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles. Immunity 2004, 21:415-428.
131. Schroeter M.L., Steiner J., Mueller K. Glial pathology is modified by age in mood disorders - a systematic meta-analysis of serum S100B invivo studies. Journal of Affective Disorders 2011, 134:32-38.
132. Sistrom C.L., Mergo P.J. Asimple method for obtaining original data from published graphs and plots. AJR. American Journal of Roentgenology 2000, 174:1241-1244.
133. Smith R.S. The macrophage theory of depression. Medical Hypotheses 1991, 35:298-306.
134. Smith R.S., Maes M. The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. Medical Hypotheses 1995, 45:135-141.
135. Soderlund J., Olsson S.K., Samuelsson M., Walther-Jallow L., Johansson C., Erhardt S., et al. Elevation of cerebrospinal fluid interleukin-1ss in bipolar disorder. Journal of Psychiatry and Neuroscience 2011, 36:114-118.
136. Soreca I., Fagiolini A., Frank E., Houck P.R., Thompson W.K., Kupfer D.J. Relationship of general medical burden, duration of illness and age in patients with bipolar I disorder. Journal of Psychiatric Research 2008, 42:956-961.
137. Soreca I., Frank E., Kupfer D.J. The phenomenology of bipolar disorder: what drives the high rate of medical burden and determines long-term prognosis?. Depression and Anxiety 2009, 26:73-82.
138. Steckert A.V., Valvassori S.S., Moretti M., Dal-Pizzol F., Quevedo J. Role of oxidative stress in the pathophysiology of bipolar disorder. Neurochemical Research 2010, 35:1295-1301.
139. Stertz L., Magalhaes P.V., Kapczinski F. Is bipolar disorder an inflammatory condition? The relevance of microglial activation. Current Opinion in Psychiatry 2013, 26:19-26.
140. Su K.P., Leu S.J., Yang Y.Y., Shen W.W., Chou Y.M., Tsai S.Y. Reduced production of interferon-gamma but not interleukin-10 in bipolar mania and subsequent remission. Journal of Affective Disorders 2002, 71:205-209.
141. Taylor V. Alterations in cytokine and adipokine levels over two years of follow up in first episode patients with bipolar disorder. Bipolar Disorders 2011, 13:98-99.
142. Taylor V.H., MacQueen G., Maconald K., McKinnion M. Alterations in cytokines and adiponectine levels over two years of follow up in patients with mood disorders. Biological Psychiatry 2009, 1:67S.
143. Teixeira A.L., Barbosa I.G., Huguet R.B., Neves F.S., Abreu M.N., Bauer M.E. Investigation of immunologic parameters and neurotrophic factors in bipolar disorder: trait or state?. Bipolar Disorders 2011, 13:99.
144. Terres G., Coffman R.L. The role of IL-4 and IL-10 cytokines in controlling an anti-tumor response invivo. International Immunology 1998, 10:823-832.
145. Tollerud D.J., Kurman C.C., Nelson D.L., Brown L.M., Maloney E.M., Blattner W.A. Racial variation in serum-soluble interleukin-2 receptor levels: a population-based study of healthy smokers and nonsmokers. Clinical Immunology and Immunopathology 1994, 70:274-279.
146. Torrey E.F., Davis J.M. Adjunct treatments for schizophrenia and bipolar disorder: what to try when you are out of ideas. Clinical Schizophrenia and Related Psychoses 2012, 5:208-216.
147. Tsai S.Y., Chen K.P., Yang Y.Y., Chen C.C., Lee J.C., Singh V.K., et al. Activation of indices of cell-mediated immunity in bipolar mania. Biological Psychiatry 1999, 45:989-994.
148. Tsai S.Y., Chung K.H., Huang S.H. No state-dependent alternation of immunological parameters, insulin, and leptin during bipolar depression. European Neuropsychopharmacology 2010, 20:S419.
149. Tsai S.Y., Chung K.H., Wu J.Y., Kuo C.J., Lee H.C., Huang S.H. Inflammatory markers and their relationships with leptin and insulin from acute mania to full remission in bipolar disorder. Journal of Affective Disorders 2012, 136:110-116.
150. Tsai S.Y., Yang Y.Y., Kuo C.J., Chen C.C., Leu S.J. Effects of symptomatic severity on elevation of plasma soluble interleukin-2 receptor in bipolar mania. Journal of Affective Disorders 2001, 64:185-193.
151. Vuksan-Cusa B., Sagud M., Jakovljevic M. C-reactive protein and metabolic syndrome in patients with bipolar disorder compared to patients with schizophrenia. Psychiatria Danubina 2010, 22:275-277.
152. Wadee A.A., Kuschke R.H., Wood L.A., Berk M., Ichim L., Maes M. Serological observations in patients suffering from acute manic episodes. Human Psychopharmacology 2002, 17:175-179.
153. Xuan A., Long D., Li J., Ji W., Hong L., Zhang M., et al. Neuroprotective effects of valproic acid following transient global ischemia in rats. Life Sciences 2012, 90:463-468.
154. Zell R., Geck P., Werdan K., Boekstegers P. TNF-alpha and IL-1 alpha inhibit both pyruvate dehydrogenase activity and mitochondrial function in cardiomyocytes: evidence for primary impairment of mitochondrial function. Molecular and Cellular Biochemistry 1997, 177:61-67.
155. Zhang Z., Zhang Z.Y., Wu Y., Schluesener H.J. Valproic acid ameliorates inflammation in experimental autoimmune encephalomyelitis rats. Neuroscience 2012, 221:140-150.